Bruno Amorim's Stock Ratings

Goldman Sachs Analyst

Bruno Amorim is an analyst at Goldman Sachs. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 09/07/2024

Overall Average Return

0.54%

Smart Score

55.6%

Overall Average Return Percentile

38th

Number of Ratings

87
Data brought to you by Benzinga APIs

Recent Analyst Stock Rating News

Goldman Sachs: Azul Appears Poised For EBITDA Expansion After Stock Declined 35%
Azul SA (NYSE: AZUL) joined other stocks making big moves on Wednesday.
GoDaddy To Rally Around 44%? Here Are 10 Other Analyst Forecasts For Wednesday
Needham cut the price target for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) from $60 to $53. Needham analyst Gil Blum maintained a Buy rating. Rocket Pharmaceuticals shares rose 24.3% to $19.00 in pre-market trading.
High Petrobras Options Volume Indicates Potential Downturn For Stock Despite Analyst Upgrade
On Thursday, the energy sector emerged as one of the weakest performers on the S&P 500, with shares of Petróleo Brasileiro S.A.
3 Reasons Why This Petrobas Analyst Is Bullish: 'Prior Risks Have Diminished'
Shares of Petroleo Brasileiro (NYSE: PBR), or Petrobras, rose in early trading on Wednesday, maintaining their uptrend so far this year.
Cemex Analyst Says Discipline Is Paying Off, As Q1 Results Surpass Predictions
Shares of Cemex SAB de CV (NYSE: CX) were rising on Thursday, after the company reported growth in its first-quarter sales and earnings.
5 On-The-Money Stock Picks For October 13 From Benzinga's Most Accurate Analysts
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst's opinion to trust.
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free